In the BioHarmony Drug Report Database

"Preview" Icon

Benralizumab

Fasenra (benralizumab) is an antibody pharmaceutical. Benralizumab was first approved as Fasenra on 2017-11-14. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma. It is known to target interleukin-5 receptor subunit alpha.

 

Trade Name

 

Fasenra
 

Common Name

 

benralizumab
 

ChEMBL ID

 

CHEMBL1742991
 

Indication

 

asthma
 

Drug Class

 

Monoclonal antibodies: humanized, immunomodulating

Image (chem structure or protein)

Benralizumab structure rendering